Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors.

Abstract

We analyzed transcriptional data from 104 HPV+ (Human papillomavirus) HNSCC (head and neck squamous cell carcinoma) tumors together with two publicly available sources to identify highly robust transcriptional programs (modules) which could be detected consistently despite heterogeneous sequencing and quantification methodologies. Among 22 modules identified, we found a single module that naturally subclassifies HPV+ HNSCC tumors based on a bimodal pattern of gene expression, clusters all atypical features of HPV+ HNSCC biology into a single subclass, and predicts patient outcome in four independent cohorts. The subclass-defining gene set was strongly correlated with Nuclear factor kappa B (NF-κB) target expression. Tumors with high expression of this NF-κB module were rarely associated with activating PIK3CA alterations or viral integration, and also expressed higher levels of HPHPV E2 and had decreased APOBEC mutagenesis. Alternatively, they harbored inactivating alterations of key regulators of NF-κB, TNF receptor associated factor 3 (TRAF3), and cylindromatosis (CYLD), as well as retinoblastoma protein (RB1). HPV+ HNSCC cells in culture with experimental depletion of TRAF3 or CYLD displayed increased expression of the subclass-defining genes, as well as robust radio-sensitization, thus recapitulating both the tumor transcriptional state and improved treatment response observed in patient data. Across all gene sets investigated, methylation to expression correlations were the strongest for the subclass-defining, NF-κB-related genes. Increased tumor-infiltrating CD4+ T cells and increased Estrogen receptors alpha (ERα) expression were identified in NF-κB active tumors. Based on the relatively high rates of cure in HPV+ HNSCC, deintensification of therapy to reduce treatment-related morbidity is being studied at many institutions. Tumor subclassification based on oncogenic subtypes may help guide the selection of therapeutic intensity or modality for patients with HPV+ HNSCC.

• Authors: Travis P Schrank, Aditi Kothari, William H Weir, Wesley H Stepp, Hina Rehmani, Xinyi Liu, Xiaowei Wang, Andrew Sewell, Xue Li, Jason Tasoulas, Sulgi Kim, Gray Yarbrough, Yue Xie, Yael Flamand, Shanthi Marur, Michele C Hayward, Di Wu, Barbara Burtness, Karen S Anderson, Albert S Baldwin, Wendell G Yarbrough, Natalia Issaeva
• Journal: Proceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 120 Issue 32 Pg. e2216532120 (08 08 2023) ISSN: 1091-6490 [Electronic] United States
• PMID: 37523561 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• NF-kappa B
• TNF Receptor-Associated Factor 3

Topics

• Humans
• Squamous Cell Carcinoma of Head and Neck (genetics, radiotherapy)
• NF-kappa B (genetics, metabolism)
• TNF Receptor-Associated Factor 3 (genetics)
• Carcinoma, Squamous Cell (genetics, radiotherapy, metabolism)
• Papillomavirus Infections (genetics)
• Head and Neck Neoplasms (genetics, radiotherapy)
• Human Papillomavirus Viruses
• Carcinogenesis
• Papillomaviridae (genetics, metabolism)